AMISULPRIDE Drug Interactions: What You Need to Know

INTERACTIONS

7.1 Dopamine Agonists Reciprocal antagonism of effects occurs between dopamine agonists (e.g., levodopa) and BARHEMSYS. Avoid using levodopa with BARHEMSYS.

7.2 Drugs Prolonging the QT Interval BARHEMSYS causes dose- and concentration-dependent QT prolongation <span class="opacity-50 text-xs">[see Clinical Pharmacology (12.2) ]</span> . To avoid potential additive effects, avoid use of BARHEMSYS in patients taking droperidol. ECG monitoring is recommended in patients taking other drugs known to prolong the QT interval (e.g., ondansetron) <span class="opacity-50 text-xs">[see Warnings and Precautions (5.1) ]</span> .

BARHEMSYS is contraindicated in patients with known hypersensitivity to amisulpride [see Adverse Reactions (6.2) ] . Known hypersensitivity to amisulpride. ( 4 )

AND PRECAUTIONS QT Prolongation : Occurs in a dose- and concentration-dependent manner. Avoid use in patients with congenital long QT syndrome and in patients taking droperidol. ECG monitoring is recommended in patients with pre-existing arrhythmias/cardiac conduction disorders; electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia); congestive heart failure; and in patients taking other medicinal products (e.g., ondansetron) or with other medical conditions known to prolong the QT interval. ( 5.1 , 7.2 )

5.1 QT Prolongation BARHEMSYS causes dose- and concentration-dependent prolongation of the QT interval <span class="opacity-50 text-xs">[see Clinical Pharmacology (12.2) ]</span> . The recommended dosage is 5 or 10 mg as a single intravenous dose infused over 1 to 2 minutes <span class="opacity-50 text-xs">[see Dosage and Administration (2.1) ]</span> . Avoid use in patients with congenital long QT syndrome and in patients taking droperidol. Electrocardiogram (ECG) monitoring is recommended in patients with pre-existing arrhythmias/cardiac conduction disorders; electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia); congestive heart failure; and in patients taking other medicinal products (e.g., ondansetron) or with other medical conditions known to prolong the QT interval <span class="opacity-50 text-xs">[see Drug Interactions (7.2) ]</span> .